1
|
Primak A, Kalinina N, Skryabina M, Usachev V, Chechekhin V, Vigovskiy M, Chechekhina E, Voloshin N, Kulebyakin K, Kulebyakina M, Grigorieva O, Tyurin-Kuzmin P, Basalova N, Efimenko A, Dzhauari S, Antropova Y, Plyushchii I, Akopyan Z, Sysoeva V, Tkachuk V, Karagyaur M. Novel Immortalized Human Multipotent Mesenchymal Stromal Cell Line for Studying Hormonal Signaling. Int J Mol Sci 2024; 25:2421. [PMID: 38397098 PMCID: PMC10889231 DOI: 10.3390/ijms25042421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/05/2024] [Accepted: 02/14/2024] [Indexed: 02/25/2024] Open
Abstract
Multipotent mesenchymal stromal cells (MSCs) integrate hormone and neuromediator signaling to coordinate tissue homeostasis, tissue renewal and regeneration. To facilitate the investigation of MSC biology, stable immortalized cell lines are created (e.g., commercially available ASC52telo). However, the ASC52telo cell line has an impaired adipogenic ability and a depressed response to hormones, including 5-HT, GABA, glutamate, noradrenaline, PTH and insulin compared to primary cells. This markedly reduces the potential of the ASC52telo cell line in studying the mechanisms of hormonal control of MSC's physiology. Here, we have established a novel immortalized culture of adipose tissue-derived MSCs via forced telomerase expression after lentiviral transduction. These immortalized cell cultures demonstrate high proliferative potential (up to 40 passages), delayed senescence, as well as preserved primary culture-like functional activity (sensitivity to hormones, ability to hormonal sensitization and differentiation) and immunophenotype up to 17-26 passages. Meanwhile, primary adipose tissue-derived MSCs usually irreversibly lose their properties by 8-10 passages. Observed characteristics of reported immortalized human MSC cultures make them a feasible model for studying molecular mechanisms, which regulate the functional activities of these cells, especially when primary cultures or commercially available cell lines are not appropriate.
Collapse
Affiliation(s)
- Alexandra Primak
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Natalia Kalinina
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Mariya Skryabina
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Vladimir Usachev
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Vadim Chechekhin
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Maksim Vigovskiy
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Elizaveta Chechekhina
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Nikita Voloshin
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Konstantin Kulebyakin
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - Maria Kulebyakina
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - Olga Grigorieva
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - Pyotr Tyurin-Kuzmin
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Nataliya Basalova
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - Anastasia Efimenko
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - Stalik Dzhauari
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Yulia Antropova
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Ivan Plyushchii
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Zhanna Akopyan
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - Veronika Sysoeva
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
| | - Vsevolod Tkachuk
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - Maxim Karagyaur
- Faculty of Medicine, Lomonosov Moscow State University, 119234 Moscow, Russia (V.C.); (Z.A.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 119234 Moscow, Russia
| |
Collapse
|
2
|
Eisenlohr-Moul TA. Commentary on Joyce et al.: Studying menstrual cycle effects on behavior requires within-person designs and attention to individual differences in hormone sensitivity. Addiction 2021; 116:2759-2760. [PMID: 34048110 PMCID: PMC8429129 DOI: 10.1111/add.15576] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 05/20/2021] [Indexed: 12/01/2022]
|
3
|
Freedland SJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, Petrilla A, Pulungan Z, Kim S, D'Andrea DM, Francis P, Ryan CJ. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. Curr Med Res Opin 2021; 37:609-622. [PMID: 33476184 DOI: 10.1080/03007995.2021.1879753] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
OBJECTIVE To develop algorithms to identify metastatic castration-sensitive prostate cancer (mCSPC) patients and castration-resistant prostate cancer (mCRPC) patients, using health claims data and laboratory test results. METHODS A targeted literature review summarized mCSPC and mCRPC patient selection criteria previously used in real-world retrospective studies. Novel algorithms to identify mCSPC and mCRPC were developed based on diagnosis codes indicating hormone sensitivity/resistance, prostate-specific antigen (PSA) test results, and claims for castration and mCRPC-specific treatments. These algorithms were applied to claims data from Optum Clinformatics Extended DataMart (Date of Death) Databases (commercial insurance/Medicare Advantage [COM/MA]; 01 January 2014-31 July 2019) and Medicare Fee-for-Service (Medicare-FFS; 01 January 2014-31 December 2017). RESULTS Previous real-world studies identified mCSPC primarily based on metastasis diagnosis codes, and mCRPC based on mCRPC-specific drugs. Using the current study's algorithms, 7034 COM/MA and 19,981 Medicare-FFS patients were identified as having mCSPC, and 2578 COM/MA and 11,554 Medicare-FFS as having mCRPC. Most mCSPC patients were identified based on evidence of being hormone/castration-naive. Patients were identified as having mCRPC most commonly based on rising PSA (COM/MA), or at the metastasis diagnosis date if it occurred after castration (Medicare-FFS). Among patients with mCSPC, 14-17% had evidence of progression to castration resistance during a median 1-year follow-up period, mostly based on use of mCRPC-specific drugs. CONCLUSIONS Comprehensive algorithms based on claims and laboratory data were developed to identify and distinguish patients with mCSPC and mCRPC. This will facilitate appropriate identification of mCSPC and mCRPC patients based on health claims data and better understanding of patient unmet needs in real-world settings.
Collapse
Affiliation(s)
- Stephen J Freedland
- Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Urology Section, Durham VA Medical Center, Durham, NC, USA
| | - Xuehua Ke
- Janssen Scientific Affairs, LLC, Horsham, PA, USA
| | | | | | | | | | | | | | | | | | | | - Charles J Ryan
- Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
4
|
Ahmed AA, Robinson T, Palande M, Escara-Wilke J, Dai J, Keller ET. Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression. J Cell Biochem 2019; 120:16946-16955. [PMID: 31099068 DOI: 10.1002/jcb.28954] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 04/23/2019] [Accepted: 04/24/2019] [Indexed: 12/16/2022]
Abstract
Notch plays a protumorigenic role in many cancers including prostate cancer (PCa). Global notch inhibition of multiple Notch family members using γ-secretase inhibitors has shown efficacy in suppressing PCa growth in murine models. However, global Notch inhibition is associated with marked toxicity due to the widespread function of many different Notch family members in normal cell physiology. Accordingly, in the current study, we explored if specific inhibition of Notch1 would effectively inhibit PCa growth in a murine model. The androgen-dependent VCaP and androgen-independent DU145 cell lines were injected subcutaneously into mice. The mice were treated with either control antibody 1B7.11, anti-Notch1 antibody (OMP-A2G1), docetaxel or the combination of OMP-A2G1 and docetaxel. Tumor growth was measured using calipers. At the end of the study, tumors were assessed for proliferative response, apoptotic response, Notch target gene expression, and DNA damage response (DDR) expression. OMP-A2G1 alone inhibited tumor growth of both PCa cell lines to a greater extent than docetaxel alone. There was no additive or synergistic effect of OMP-A2G1 and docetaxel. The primary toxicity was weight loss that was controlled with dietary supplementation. Proliferation and apoptosis were affected differentially in the two cell lines. OMP-A2G1 increased expression of the DDR gene GADD45α in VCaP cells but downregulated GADD45α in Du145 cells. Taken together, these data show that Notch1 inhibition decreases PCa xenograft growth but does so through different mechanisms in the androgen-dependent VCaP cell line vs the androgen-independent DU145 cell line. These results provide a rationale for further exploration of targeted Notch inhibition for therapy of PCa.
Collapse
Affiliation(s)
- Aqila A Ahmed
- Department of Urology, University of Michigan, Ann Arbor, Michigan
| | - Tyler Robinson
- Department of Urology, University of Michigan, Ann Arbor, Michigan
| | - Monica Palande
- Department of Urology, University of Michigan, Ann Arbor, Michigan
| | | | - Jinlu Dai
- Department of Urology, University of Michigan, Ann Arbor, Michigan
| | - Evan T Keller
- Department of Urology, University of Michigan, Ann Arbor, Michigan.,Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan
| |
Collapse
|
5
|
Kikawa Y, Kotake T, Kajiwara Y, Hashimoto K, Yamashiro H, Ohtani S, Takao S, Toi M. Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. Breast Cancer (Auckl) 2019; 13:1178223418825135. [PMID: 30733627 PMCID: PMC6343452 DOI: 10.1177/1178223418825135] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Accepted: 12/06/2018] [Indexed: 11/15/2022]
Abstract
Purpose: To investigate the clinical predictive factors for the efficacy of everolimus (EVE) for advanced/metastatic breast cancer (AMBC). Methods: Routine practice data of consecutive patients with AMBC who received EVE at 5 institutions in western Japan were retrospectively analyzed in this cohort study (study registration no.: UMIN 000032569). The correlation among time to treatment failure (TTF), overall survival (OS), and clinical background was investigated via univariate and multivariate analyses using Cox hazards model for the clinically important variables. Results: A total of 134 patients were included in the analysis. The median TTF and OS were 5.2 months (95% confidence interval [CI]: 4.1-6.4) and 27.3 months (95% CI: 23.7-30.9), respectively. Multivariate analysis showed that dose reduction of EVE from any initial dose was associated with a longer TTF (hazard ratio [HR]: 0.52; 95% CI: 0.32-0.84, P = .007). Meanwhile, very low hormone sensitivity (ie, relapse within the first 2 years during adjuvant endocrine therapy or progression within 3 months of endocrine therapy immediately before EVE) was associated with a shorter TTF (HR: 2.48; 95% CI: 1.49-4.10, P < .001). In the analysis of stratified treatment outcomes, TTF was longer in the group with <3 liver metastases and in groups other than the very low hormone sensitivity group, regardless of the treatment line of EVE. Conclusions: Low hormone sensitivity and ⩾3 liver metastases were important prognostic factors for the efficacy of EVE. EVE may be less effective in patients with AMBC with these factors, and as such, chemotherapy should be administered instead.
Collapse
Affiliation(s)
- Yuichiro Kikawa
- Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan
- Yuichiro Kikawa, Department of Breast Surgery, Kobe City Medical Center General Hospital, 2-2-1, Minatojimaminamimachi, Chuo-ku, Kobe 650-0047, Hyogo, Japan.
| | - Takeshi Kotake
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yukiko Kajiwara
- Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Kazuki Hashimoto
- Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan
| | | | - Shoichiro Ohtani
- Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Shintaro Takao
- Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan
| | - Masakazu Toi
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
6
|
Roldan M, Dinh P, Leung S, McManus MT. Ethylene and the responses of plants to phosphate deficiency. AoB Plants 2013; 5:plt013. [PMCID: PMC4104654 DOI: 10.1093/aobpla/plt013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Accepted: 02/14/2013] [Indexed: 05/20/2023]
Abstract
This review considers the evidence that ethylene biosynthesis is up-regulated by locally-generated signals in response to a change in external P supply, where the hormone then mediates, with auxin, changes in root system architecture. Subsequent changes in endogenous P evoke systemic responses whereby ethylene again is important in inducing some of the key signature changes observed in P-deprived tissues (eg. phosphate transporter and acid phosphatase up-regulation). The consideration as to how plants uptake and transport phosphorus (P) is of significant agronomic and economic importance, in part driven by finite reserves of rock phosphate. Our understanding of these mechanisms has been greatly advanced, particularly with respect to the responses of plants to P deficiency and the genetic dissection of the signalling involved. Further, the realization that there are two tiers of transcriptional responses, the local, in which inorganic P (Pi) acts as an external signal independent of the endogenous P level, and the systemic involving root–shoot signalling, has now added a dimension of both clarity and complexity. Notwithstanding, it is now clear that the hormone ethylene plays a key role in mediating both levels of responses. This review, therefore, covers the role of ethylene in terms of mediating responses to P deficiency. The evidence that Pi supply regulates ethylene biosynthesis and sensitivity, and that this, in turn, regulates changes in root system architecture and in Pi-deprivation responses is examined here. While ethylene is the focus, the key interactions with auxin are also assessed, but interactions with the other hormone groups, which have recently been reviewed, are not covered. The emerging view that ethylene is a multi-faceted hormone in terms of mediating responses to P deficiency invites the dissection of the transcriptional cues that mediate changes in ethylene biosynthesis and/or sensitivity. Knowledge of the nature of such cues will subsequently reveal more of the underpinning interactions that govern P responses and provide avenues for the production of germplasm with an improved phosphate use efficiency.
Collapse
Affiliation(s)
- Marissa Roldan
- Institute of Molecular Biosciences, Massey University, Private Bag 11-222, Palmerston North, New Zealand
- Present address: AgResearch Grasslands, Private Bag 11008, Palmerston North, New Zealand
| | - Phuong Dinh
- Institute of Molecular Biosciences, Massey University, Private Bag 11-222, Palmerston North, New Zealand
- Present address: Department of Plant Pathology, Washington State University, Pullman, WA, USA
| | - Susanna Leung
- Institute of Molecular Biosciences, Massey University, Private Bag 11-222, Palmerston North, New Zealand
| | - Michael T. McManus
- Institute of Molecular Biosciences, Massey University, Private Bag 11-222, Palmerston North, New Zealand
- Corresponding author's e-mail address:
| |
Collapse
|
7
|
Abstract
Owing to its efficacy and relative lack of toxicities, endocrine therapy is a major treatment modality for breast cancer. However, resistance and the inability to accurately predict response are obstacles to optimal management. There is a need to identify markers of clinical response and elucidate mechanisms of resistance. In this article, evidence will be presented demonstrating that: discovery of predictive markers is dependent upon the approach employed and the application required; and mechanisms of resistance are diverse and not simply mirror images of response. Different information may be obtained according to assessment read outs and type of analysis. Tumors respond to endocrine therapy in a variety of ways and a range of end points can be used to monitor hormone dependence, sensitivity and resistance to treatment. Different forms of endocrine therapies may have differing mechanisms of action - hence, markers of sensitivity/response can vary between treatments and there may be correspondingly differing mechanisms of resistance.
Collapse
Affiliation(s)
- William R Miller
- a University of Edinburgh, 2 Stoneycroft Road, South Queensferry, West Lothian, EH30 9HX, UK.
| |
Collapse
|
8
|
Németh K, Salchert K, Putnoky P, Bhalerao R, Koncz-Kálmán Z, Stankovic-Stangeland B, Bakó L, Mathur J, Okrész L, Stabel S, Geigenberger P, Stitt M, Rédei GP, Schell J, Koncz C. Pleiotropic control of glucose and hormone responses by PRL1, a nuclear WD protein, in Arabidopsis. Genes Dev 1998; 12:3059-73. [PMID: 9765207 PMCID: PMC317193 DOI: 10.1101/gad.12.19.3059] [Citation(s) in RCA: 203] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The prl1 mutation localized by T-DNA tagging on Arabidopsis chromosome 4-44 confers hypersensitivity to glucose and sucrose. The prl1 mutation results in transcriptional derepression of glucose responsive genes defining a novel suppressor function in glucose signaling. The prl1 mutation also augments the sensitivity of plants to growth hormones including cytokinin, ethylene, abscisic acid, and auxin; stimulates the accumulation of sugars and starch in leaves; and inhibits root elongation. PRL1 encodes a regulatory WD protein that interacts with ATHKAP2, an alpha-importin nuclear import receptor, and is imported into the nucleus in Arabidopsis. Potential functional conservation of PRL1 homologs found in other eukaryotes is indicated by nuclear localization of PRL1 in monkey COS-1 cells and selective interaction of PRL1 with a nuclear protein kinase C-betaII isoenzyme involved in human insulin signaling.
Collapse
Affiliation(s)
- K Németh
- Abteilung Genetische Grundlagen der Pflanzenzüchtung, Federal Republic of Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|